A possible new diagnostic biomarker in early diagnosis of Alzheimer's disease

Current Alzheimer Research

Volumn 6, Issue 6, 2009, Pages 519-524

  Kork, Felix ^a   Holthues, Jan ^b   Hellweg, Rainer ^a   Jankowski, Vera ^a   Tepel, Martin ^a   Öhring, Renate ^c   Heuser, Isabella ^a   Bierbrauer, Jeffrey ^a   Peters, Oliver ^a   Schlattmann, Peter ^a   Zidek, Walter ^a   Jankowski, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Jewish Hospital   (Germany)

^c Campus Charité Mitte ^*  (Germany)

Author keywords

Alzheimer disease; Biomarker; Cerebrospinal fluid; Diagnostic marker; Metabonomics; NMR spectroscopy

Indexed keywords

BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCREENING TEST; BLOOD; HIPPOCAMPUS; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; PATHOLOGY;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; ORGAN SIZE;

EID: 73949132592     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509790147160     Document Type: Article

References (33)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on alzheimer's disease. Neurology 34: 939-944 (1984).
2. Leifer BP. Early diagnosis of alzheimer's disease: Clinical and economic benefits. J Am Geriatr Soc 51: S281-S288 (2003).
3. Relkin N. Screening and early diagnosis of dementia. Am J Manag Care 6: S1111-1118; discussion S1119-1124 (2000).
4. McGeer EG, McGeer PL. Clinically tested drugs for alzheimer's disease. Expert Opin Investig Drugs 12: 1143-1151 (2003).
5. Marder K. Vaccine trial in alzheimer's disease is halted. Curr Neurol Neurosci Rep 3: 371-372 (2003).
6. Guarch J, Marcos T, Salamero M, Blesa R. Neuropsychological markers of dementia in patients with memory complaints. Int J Geriatr Psychiatry 19: 352-358 (2004).
7. Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C. Biochemical markers related to alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 23: 485-508 (2002).
8. Essig M, Schoenberg SO. [Radiologic diagnostics of dementia]. Radiologe 43: 531-536 (2003).
9. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2: 605-613 (2003).
10. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and beta-amyloid: How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60: 1696-1702 (2003).
11. Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, et al. Core biological marker candidates of alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 111: 247-272 (2004).
12. Engelborghs S, De Deyn PP. Biological and genetic markers of sporadic alzheimer's disease. Acta Med Okayama 55: 55-63 (2001).
13. Small DH. Alzheimer's disease biomarkers: Their value in diagnosis and clinical trials. Front Biosci 7: d986-d988 (2002).
14. Wiltfang J, Esselmann H, Maler JM, Bleich S, Hüther G, Kornhuber J. Molecular biology of alzheimer's dementia and its clinical relevance to early diagnosis and new therapeutic strategies. Gerontology 47: 65-71 (2001).
15. Kantarci K, Jack CR. Neuroimaging in alzheimer disease: An evidence-based review. Neuroimaging Clin N Am 13: 197-209 (2003).
16. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a registry for alzheimer's disease (CERAD) clinical and neuropsychological assessment of alzheimer's disease. Psychopharmacol Bull 24: 641-652 (1988).
17. Härting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J. In: 'Wechsler gedächtnistest-revidierte fassung (WMSR): Deutsche adaptation der revidierten fassung der wechsler memory scale'. Bern, Switzerland: Hans Huber (2000).
18. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 8: 271-276 (1958).
19. Morris JC, Edland S, Clark C, Galasko D, Koss E, Mohs R, et al. The consortium to establish a registry for alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable alzheimer's disease. Neurology 43: 2457-2465 (1993).
20. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The consortium to establish a registry for alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of alzheimer's disease. Neurology 39: 1159-1165 (1989).
21. Grober E, Merling A, Heimlich T, Lipton RB. Free and cued selective reminding and selective reminding in the elderly. J Clin Exp Neuropsychol 19: 643-654 (1997).
22. Busse A, Aurich C, Zaudig M, Riedel-Heller S, Matschinger H, Angermeyer MC. [Age- and education-specific reference values for the cognitive test of the SIDAM (structured interview for the diagnosis of dementia of the alzheimer type, multi-infarct dementia and dementias of other etiology according to ICD-10 and DSM-IV)]. Z Gerontol Geriatr 35: 565-574 (2002).
23. Shulman KI. Clock-Drawing: Is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15: 548-561 (2000).
24. Hindmarch I, Lehfeld H, de Jongh P, Erzigkeit H. The bayer activities of daily living scale (B-ADL). Dement Geriatr Cogn Disord 9 (Suppl 2): 20-26 (1998).
25. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: A frontal assessment battery at bedside. Neurology 55: 1621-1626 (2000).
26. Kurz A, Riemenschneider M, Drzezga A, Lautenschlager N. The role of biological markers in the early and differential diagnosis of alzheimer's disease. J Neural Transm Suppl 62: 127-133 (2002).
27. Bell JD, Brown JC, Sadler PJ, Macleod AF, Sönksen PH, Hughes RD, et al. High resolution proton nuclear magnetic resonance studies of human cerebrospinal fluid. Clin Sci (Lond) 72: 563-570 (1987).
28. Bodenhausen G, Kogler H, Renst RR. Selection of coherence-transfer pathways in NMR pulse experiments. J Magn Reson 58: 370-388 (1984).
29. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36 (1982).
30. DeKosky ST, Marek K. Looking backward to move forward: Early detection of neurodegenerative disorders. Science 302: 830-834 (2003).
31. Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of alzheimer's disease. Neurosci Lett 352: 67-69 (2003).
32. Jankowski J, Nofer JR, Tepel M, Griewel B, Schlüter H, Assmann G, et al. Identification of oxidized low-density lipoprotein in human serum by NMR spectroscopy. Clin Sci (Lond) 95: 489-495 (1998).
33. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and alzheimer disease. A meta-analysis. APOE and alzheimer disease meta analysis consortium. JAMA 278: 1349-1356 (1997).